Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis


Creative Commons License

Efe C., Hagstrom H., Ytting H., Bhanji R. A., Muller N. F., Wang Q., ...More

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.15, no.12, pp.1950-1957, 2017 (SCI-Expanded) identifier identifier identifier

Abstract

BACKGROUND & AIMS: Predniso(lo) ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.